C5 and anemia (phenotype): Expert reviews have estimated that up to one third of C5 inhibitor-treated patients will develop EVH [12], although surveys of patients receiving at least 3 months of C5 inhibitor therapy suggest that anaemia and fatigue persist in an even greater proportion of patients [13].